JPMorgan Chase & Co. Has Lowered Expectations for Alphatec (NASDAQ:ATEC) Stock Price

Key Points

• JPMorgan cut its price target on Alphatec to $16 (from $24) but kept an "overweight" rating; the stock's consensus analyst view remains a "Moderate Buy" with an average target of $18.75.
• Q1 results showed revenue +13.6% YoY but missed expectations (EPS -$0.22 vs. -$0.01; revenue $192.1M vs. ~$197.5M) and management trimmed full‑year revenue guidance, triggering a sharp sell‑off to about $6.99 on heavy volume.
• Downside pressures include large recent insider and institutional selling and a Johnson Fistel investigation, even as the company secured a new senior secured credit facility and reported strong gross margins.

Alphatec (NASDAQ:ATEC - Get Free Report) had its price objective decreased by equities research analysts at JPMorgan Chase & Co. from $24.00 to $16.00 in a report released on Wednesday,Benzinga reports. The firm currently has an "overweight" rating on the medical technology company's stock. JPMorgan Chase & Co.'s price target would suggest a potential upside of 128.90% from the company's previous close.

Other equities analysts also recently issued reports about the stock. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Alphatec in a report on Friday, March 27th. TD Cowen dropped their target price on shares of Alphatec from $20.00 to $11.00 and set a "buy" rating for the company in a research report on Wednesday. Wells Fargo & Company upgraded shares of Alphatec to a "strong-buy" rating in a research report on Wednesday, March 18th. Lake Street Capital restated a "buy" rating and issued a $15.00 price objective on shares of Alphatec in a research report on Wednesday. Finally, Needham & Company LLC lowered their price objective on shares of Alphatec from $25.00 to $14.00 and set a "buy" rating for the company in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $18.75.

Alphatec Stock Performance

Alphatec stock traded down $3.24 during mid-day trading on Wednesday, reaching $6.99. The company had a trading volume of 21,562,737 shares, compared to its average volume of 3,222,331. The company has a quick ratio of 1.28, a current ratio of 2.06 and a debt-to-equity ratio of 40.35. Alphatec has a 52 week low of $6.85 and a 52 week high of $23.29. The company has a 50 day moving average of $11.73 and a 200-day moving average of $15.95. The firm has a market cap of $1.07 billion, a price-to-earnings ratio of -7.36 and a beta of 0.96.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The medical technology company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.21). The business had revenue of $192.11 million for the quarter, compared to analysts' expectations of $197.51 million. Alphatec's revenue for the quarter was up 13.6% on a year-over-year basis. During the same period in the previous year, the business posted ($0.35) earnings per share. On average, sell-side analysts expect that Alphatec will post -0.28 EPS for the current fiscal year.

Insider Buying and Selling at Alphatec

In other news, COO Scott Lish sold 260,535 shares of Alphatec stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $12.30, for a total transaction of $3,204,580.50. Following the completion of the sale, the chief operating officer owned 815,704 shares in the company, valued at $10,033,159.20. The trade was a 24.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Craig E. Hunsaker sold 82,765 shares of Alphatec stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $12.45, for a total transaction of $1,030,424.25. Following the sale, the executive vice president owned 1,726,209 shares of the company's stock, valued at approximately $21,491,302.05. This represents a 4.58% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 689,614 shares of company stock worth $8,634,850 in the last 90 days. Corporate insiders own 20.90% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ATEC. Aster Capital Management DIFC Ltd bought a new position in Alphatec in the third quarter valued at approximately $34,000. Northwestern Mutual Wealth Management Co. lifted its stake in Alphatec by 157.1% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,571 shares of the medical technology company's stock valued at $54,000 after buying an additional 1,571 shares in the last quarter. Summit Securities Group LLC bought a new position in Alphatec in the first quarter valued at approximately $29,000. Osterweis Capital Management Inc. bought a new position in Alphatec in the second quarter valued at approximately $37,000. Finally, China Universal Asset Management Co. Ltd. bought a new position in Alphatec in the third quarter valued at approximately $73,000. Institutional investors own 66.35% of the company's stock.

Key Headlines Impacting Alphatec

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: Q1 showed revenue growth (+13.6% YoY) with strong GAAP and non‑GAAP gross margins (~71–72%) and an improvement in EPS vs. last year — these operational improvements support longer‑term recovery prospects. ATEC Reports First Quarter Financial Results
• Positive Sentiment: Alphatec established a new senior secured syndicated credit facility to support growth and liquidity — this reduces short‑term financing risk. Alphatec Establishes New Syndicated Credit Facility for Growth
• Positive Sentiment: Sell‑side support remains: Needham and TD Cowen kept "buy" ratings despite lowering price targets, signaling analysts still see upside at current depressed levels. Analyst Coverage
• Neutral Sentiment: Company released the full earnings slide deck and the earnings call transcript — useful for digging into margin trends, customer dynamics, and the updated guidance assumptions. Q1 Slide Deck
• Negative Sentiment: Q1 EPS missed expectations: reported (‑$0.22) vs. consensus (‑$0.01) and revenue of $192.1M fell short of the ~$197.5M consensus — the earnings miss is a primary catalyst for the decline. Earnings Report Summary
• Negative Sentiment: Management trimmed its full‑year revenue outlook, triggering sharp investor re‑pricing and the immediate market reaction. Revenue Outlook Cut
• Negative Sentiment: Johnson Fistel announced an investigation into potential claims against Alphatec executives — regulatory/litigation risk increases uncertainty and can pressure the stock. Johnson Fistel Investigation
• Negative Sentiment: Reported institutional selling (a fund disclosed ~$18M of sales last quarter), which contributes to added supply and downward pressure. Fund Selling Disclosed

Alphatec Company Profile

Alphatec Holdings, Inc NASDAQ: ATEC is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company's portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec's flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.